<?xml version="1.0" encoding="UTF-8"?>
<p>The incidence of venous thromboembolism (VTE) in hospitalized patients with COVID-19 has been a controversial matter during the pandemic. Initial studies seemed to point towards patients the benefits of VTE prophylaxis in emergency care. Currently, there is insufficient data to recommend for or against the use of thrombolytics or increasing anti-coagulant doses in hospitalized COVID-19 patients. More epidemiologic studies with better control for underlying comorbidities, prophylactic anticoagulation, and COVID-19-related therapies are needed (
 <xref rid="B353" ref-type="bibr">NIH, 2020</xref>).
</p>
